NCT02992522View on ClinicalTrials.gov

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

August 15, 2026

Study Completion Date

August 15, 2026

Conditions
B-Cell Lymphoma, UnspecifiedGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Marginal Zone LymphomaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaTransformed Recurrent Non-Hodgkin LymphomaB-Cell
Interventions
DRUG

Lenalidomide

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (2)

30322

Emory University, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (2)

Celgene
Genentech, Inc.
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Beth Christian

OTHER

NCT02992522 - Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter